Sun Pharmaceutical Industries Ltd. — Ethics Grade D

Sun Pharmaceutical Industries Ltd. receives an overall ethics grade of D (38/100) on CancelCo's corporate accountability database. Sector: Pharmaceuticals. Market cap: Large Cap.

Category scores

• labor: 40
• privacy: 60
• consumer: 25
• environment: 45
• humanRights: 50

Documented incidents (3)

• FDA Import Alerts and Quality Control (high, 2022) — The FDA issued a warning letter and import alerts for Sun Pharma facilities in Halol due to repeated failures in maintaining sterile manufacturing conditions and equipment cleaning.
• Generic Price Fixing Allegations (high, 2020) — The company was named in broad litigation by US states alleging a conspiracy with other generic manufacturers to fix prices and rig bids for various essential drugs.
• Insider Trading Settlement (medium, 2021) — Sun Pharma and its promoters settled an investigation by the Securities and Exchange Board of India (SEBI) regarding alleged violations of insider trading regulations without admitting or denying guilt.

Documented good deeds

• Affordable Bio-similars — Expanded its division for affordable bio-similars aimed at emerging markets to reduce the cost of diabetes treatment.

Ethical alternatives

• Biogen — Superior quality control track record and stronger R&D ethical guidelines.